Bolt Biotherapeutics, Inc. Proceeds from Sale and Maturity of Marketable Securities
Bolt Biotherapeutics, Inc. (BOLT) reported Proceeds from Sale and Maturity of Marketable Securities of $16.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $7.10M, a 71.89% decline year-over-year.
- Bolt Biotherapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $9.12M, a 37.43% decline year-over-year.
- Bolt Biotherapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $12.91M, a 49.33% decline year-over-year.
- Bolt Biotherapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $19.68M, a 47.32% decline year-over-year.
- Bolt Biotherapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $72.43M, a 50.50% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $146.32M, a 38.06% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $236.23M, a 1.78% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $240.52M, a 188.01% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $16.22M 10-Q · filed 2026-08-11 | $29.14M derived: sum of 3 quarters · filed 2026-08-11 | $48.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $9.12M 10-Q · filed 2026-05-12 | $22.04M derived: sum of 2 quarters · filed 2026-05-12 | $41.71M derived: sum of 3 quarters · filed 2026-05-12 | $66.97M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $12.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $32.59M derived: sum of 2 quarters · filed 2026-03-12 | $57.85M derived: sum of 3 quarters · filed 2026-08-11 | $72.43M 10-K · filed 2026-03-12 |
| 2025-09-30 | $19.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $44.93M derived: sum of 2 quarters · filed 2026-08-11 | $59.51M 10-Q · filed 2025-11-12 | $85.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $25.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $39.84M 10-Q · filed 2026-08-11 | $65.32M derived: sum of 3 quarters · filed 2026-08-11 | $102.67M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $14.58M 10-Q · filed 2026-05-12 | $40.06M derived: sum of 2 quarters · filed 2026-05-12 | $77.42M derived: sum of 3 quarters · filed 2026-05-12 | $127.64M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $25.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $62.84M derived: sum of 2 quarters · filed 2026-03-12 | $113.06M derived: sum of 3 quarters · filed 2026-03-12 | $146.32M 10-K · filed 2026-03-12 |
| 2024-09-30 | $37.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $87.58M derived: sum of 2 quarters · filed 2025-11-12 | $120.84M 10-Q · filed 2025-11-12 | $168.81M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $50.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $83.49M 10-Q · filed 2025-08-14 | $131.46M derived: sum of 3 quarters · filed 2025-08-14 | $180.59M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $33.26M 10-Q · filed 2025-05-12 | $81.24M derived: sum of 2 quarters · filed 2025-05-12 | $130.36M derived: sum of 3 quarters · filed 2025-05-12 | $197.62M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $47.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $97.10M derived: sum of 2 quarters · filed 2025-03-24 | $164.35M derived: sum of 3 quarters · filed 2025-03-24 | $236.23M 10-K · filed 2025-03-24 |
| 2023-09-30 | $49.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $116.38M derived: sum of 2 quarters · filed 2024-11-12 | $188.26M 10-Q · filed 2024-11-12 | $230.24M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $67.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $139.13M 10-Q · filed 2024-08-13 | $181.11M derived: sum of 3 quarters · filed 2024-08-13 | $231.21M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $71.88M 10-Q · filed 2024-05-14 | $113.86M derived: sum of 2 quarters · filed 2024-05-14 | $163.95M derived: sum of 3 quarters · filed 2024-05-14 | $194.86M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $41.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $92.08M derived: sum of 2 quarters · filed 2024-03-21 | $122.98M derived: sum of 3 quarters · filed 2024-03-21 | $240.52M 10-K · filed 2024-03-21 |
| 2022-09-30 | $50.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $81.01M derived: sum of 2 quarters · filed 2023-11-09 | $198.54M 10-Q · filed 2023-11-09 | $249.82M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $30.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $148.44M 10-Q · filed 2023-08-07 | $199.73M derived: sum of 3 quarters · filed 2023-08-07 | $220.55M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $117.53M 10-Q · filed 2023-05-11 | $168.82M derived: sum of 2 quarters · filed 2023-05-11 | $189.64M derived: sum of 3 quarters · filed 2023-05-11 | $193.44M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $51.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $72.11M derived: sum of 2 quarters · filed 2023-03-29 | $75.91M derived: sum of 3 quarters · filed 2023-03-29 | $83.51M 10-K · filed 2023-03-29 |
| 2021-09-30 | $20.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $24.62M derived: sum of 2 quarters · filed 2022-11-10 | $32.23M 10-Q · filed 2022-11-10 | $34.83M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $11.41M 10-Q · filed 2022-08-10 | $14.01M derived: sum of 3 quarters · filed 2022-08-10 | $22.06M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $7.61M 10-Q · filed 2022-05-12 | $10.21M derived: sum of 2 quarters · filed 2022-05-12 | $18.26M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $10.65M derived: sum of 2 quarters · filed 2022-03-30 | $15.90M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $8.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $13.30M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $5.25M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |